



# International Journal of Pharmacy and Natural Medicines

Journal Home Page: [www.pharmaresearchlibrary.com/ijpnm](http://www.pharmaresearchlibrary.com/ijpnm)



## RESEARCH ARTICLE

### RP-HPLC Method Development and Validation for Simultaneous Estimation of Tiotropium and Salmeterol in Bulk and Pharmaceutical Dosage Forms

MS.CH.Anusha<sup>1</sup>, Dr.D.Naresh<sup>2</sup>, Dr. GampaVijayKumar<sup>3\*</sup>

<sup>1</sup>KGR Institute of Technology and Management, Rampally, Kesara, Rangareddy, Telangana, India.

<sup>2</sup>KGR Institute of Technology and Management, Rampally, Kesara, Rangareddy, Telangana, India.

<sup>3</sup>Professor and Head, Dept. of Pharmacy, KGR Institute of Technology and Management, Rampally, Kesara, Rangareddy, Telangana, India.

#### ABSTRACT

High performance liquid chromatography is at present one of the most sophisticated tool of the analysis. The estimation of Tiotropium and Salmeterol was done by RP-HPLC. The Phosphate buffer was  $p^H 3.0$  and the mobile phase was optimized with consists of Methanol: Phosphate buffer mixed in the ratio of 70:30 % v/v. Inertsil C<sub>18</sub> column C18 (4.6 x 150mm, 5 $\mu$ m) or equivalent chemically bonded to porous silica particles was used as stationary phase. The detection was carried out using UV detector at 253 nm. The solutions were chromatographed at a constant flow rate of 0.8 ml/min. the linearity range of Tiotropium and Salmeterol were found to be from 100-500  $\mu$ g/ml of Tiotropium and 1-5 $\mu$ g/ml of Salmeterol. Linear regression coefficient was not more than 0.999. The values of % RSD are less than 2% indicating accuracy and precision of the method. The percentage recovery varies from 98-102% of Tiotropium and Salmeterol. LOD and LOQ were found to be within limit. The results obtained on the validation parameters met ICH and USP requirements. It inferred the method found to be simple, accurate, precise and linear. The method was found to be having suitable application in routine laboratory analysis with high degree of accuracy and precision.

**Keywords:** Methanol: Phosphate buffer, Inertsil C<sub>18</sub> column, Tiotropium and Salmeterol, RP-HPLC.

#### ARTICLE INFO

##### \*Corresponding Author

Dr. Gampa Vijay Kumar  
KGR Institute of Technology and Management, Rampally, Kesara, Rangareddy, Telangana, India.  
MS-ID: IJPNM4066



PAPER QR-CODE

**ARTICLE HISTORY:** Received 02 March 2019, Accepted 09 May 2019, Available Online 15 June 2019

**Copyright**© 2019 Dr. Gampa Vijay Kumar, et al. Production and hosting by Pharma Research Library. All rights reserved.

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.


**Citation:** Dr. Gampa Vijay Kumar, et al. RP-HPLC Method Development and Validation for Simultaneous Estimation of Tiotropium and Salmeterol in Bulk and Pharmaceutical Dosage Forms. *Int. J. Pharm. Natural Med.*, 2019, 7(1): 26-30.

#### CONTENTS

|                           |    |
|---------------------------|----|
| 1. Introduction           | 27 |
| 2. Materials and Method   | 27 |
| 3. Results and Discussion | 27 |
| 4. Conclusion             | 30 |
| 5. References             | 30 |


## 1. Introduction

Tiotropium bromide, sold under the brand name Spiriva among others, is a long-acting bronchodilator used in the management of chronic obstructive pulmonary disease (COPD) and asthma. Specifically it is used to try to prevent periods of worsening rather than for those periods themselves. It is used by inhalation through the mouth. Onset typically begins within half an hour and lasts for 24 hours.



**Fig 1:** Structure of Tiotropium bromide

Salmeterol is a long-acting  $\beta_2$  adrenergic receptor agonist (LABA) used in the maintenance and prevention of asthma symptoms and maintenance of chronic obstructive pulmonary disease (COPD) symptoms. Symptoms of bronchospasm include shortness of breath, wheezing, coughing and chest tightness. It is also used to prevent breathing difficulties during exercise (exercise-induced bronchoconstriction).



**Fig 2:** Structure of Salmeterol

## 2. Materials and Methods

### Instrumentation:

SystemAllianceWaters 2690 separation module, Pump Analytical HPLC isocratic pump, DetectorPhoto diode array detector, SoftwareEmpower 2 software, ColumnAgilent (250×4.6mm, 5 $\mu$ ) C-18 RP-column, SonicatorAnalytical Technologies Limited- Ultrasonic cleaner. U.V double beam spectrophotometer LABINDIA, UV 3000<sup>+</sup>pH meter, Weighing machine.

### Chemicals:

Tiotropium and Salmeterol,  $\text{KH}_2\text{PO}_4$ , Water and Methanol for HPLC, Acetonitrile for HPLC, Ortho phosphoric acid, Tri ethyl amine.

### Optimized chromatographic conditions

Mobile phase : Phosphate buffer pH 3.0: ACN (30:70% v/v)

Column : Inertsil C18 5 $\mu$ m (4.6\*250mm)

Flow rate : 0.8 ml/min


Wavelength : 253nm

Column temp : Ambient

International Journal of Pharmacy and Natural Medicines

Sample Temp : Ambient

Injection Volume: 10  $\mu$ l



**Fig 3:** Chromatogram from Tiotropium and Salmeterol

### Standard solution preparation:

Accurately weigh and transfer 200 mg of Tiotropium and Salmeterol 25mg of working standard into a 10mL & 100ml clean dry volumetric flask add about 7mL of Diluent and sonicate to dissolve it completely and make volume up to the mark with the same solvent. (Stock solution) Further pipette 3ml & 0.3ml of the above stock solutions into a 10ml volumetric flask and dilute up to the mark with diluent.


### Sample solution preparation:

Accurately weigh 10 tablets crush in mortar and pestle and transfer equivalent to 20.02 mg and 20.02mg of Tiotropium and Salmeterol (marketed formulation) sample into a 10mL clean dry volumetric flask add about 7mL of Diluent and sonicate to dissolve it completely and make volume up to the mark with the same solvent. (Stock solution) Further pipette 3 ml of Tiotropium and Salmeterol of the above stock solution into a 10ml volumetric flask and dilute up to the mark with diluent.


### Method Validation

- ✓ System Suitability
- ✓ Linearity
- ✓ Specificity
- ✓ Precision ( Repeatability & Intermediate precision)
- ✓ Accuracy
- ✓ Limit of Detection and Limit of Quantification
- ✓ Robustness

## 3. Results and Discussion



**Fig 4:** Calibration graph for Salmeterol

**Fig 5:** Calibration graph for Tiotropium**Table 1:** Results of system suitability parameters for Tiotropium and Salmeterol

| S.No | Name       | Retention time(min) | Area (μV sec) | Height (μV) | USP resolution | USP tailing | USP plate count |
|------|------------|---------------------|---------------|-------------|----------------|-------------|-----------------|
| 1    | Tiotropium | 2.5                 | 124505        | 213642      |                | 1.2         | 4673.4          |
| 2    | Salmeterol | 3.9                 | 1308495       | 154566      | 6.0            | 1.3         | 6090.3          |

**Table 2:** Results of method precision for Tiotropium

| Injection          | Area      |
|--------------------|-----------|
| Injection-1        | 1302729   |
| Injection-2        | 1302947   |
| Injection-3        | 1303236   |
| Injection-4        | 1303977   |
| Injection-5        | 1309759   |
| Average            | 1304529.8 |
| Standard Deviation | 2961.1    |
| %RSD               | 0.2       |

**Table 3:** Results of method precision for Salmeterol

| Injection          | Area     |
|--------------------|----------|
| Injection-1        | 123149   |
| Injection-2        | 123766   |
| Injection-3        | 124271   |
| Injection-4        | 124691   |
| Injection-5        | 124956   |
| Average            | 124162.7 |
| Standard Deviation | 725.6    |
| %RSD               | 0.6      |

**Table 4:** Results of Intermediate precision for Tiotropium

| Injection          | Area      |
|--------------------|-----------|
| Injection-1        | 1300148   |
| Injection-2        | 1304520   |
| Injection-3        | 1305937   |
| Injection-4        | 1306476   |
| Injection-5        | 130871    |
| Average            | 1305070.2 |
| Standard Deviation | 3061.8    |
| %RSD               | 0.2       |

**Table 5:** Results of Intermediate precision for Salmeterol

| Injection   | Area   |
|-------------|--------|
| Injection-1 | 122487 |
| Injection-2 | 122626 |

|                    |          |
|--------------------|----------|
| Injection-3        | 122632   |
| Injection-4        | 122702   |
| Injection-5        | 122962   |
| Average            | 122681.8 |
| Standard Deviation | 174.8    |
| %RSD               | 0.1      |

**Table 6:** Accuracy (recovery) data for Tiotropium

| %Concentration<br>(at specification<br>Level) | Area     | Amount<br>Added<br>(mg) | Amount<br>Found<br>(mg) | % Recovery | Mean<br>Recovery |
|---|----------|-------------------------|-------------------------|------------|------------------|
| 50%   | 656659.5 | 5.0                     | 5.036                   | 100.7%     | 99.84%           |
| 100%  | 1304258  | 10.0                    | 10.003                  | 100.0%     |                  |
| 150%  | 1854608  | 14.4                    | 14.224                  | 98.780%    |                  |

**Table 7:** Accuracy (recovery) data for Salmeterol

| %Concentration<br>(at specification<br>Level) | Area   | Amount<br>Added<br>(mg) | Amount<br>Found<br>(mg) | % Recovery | Mean<br>Recovery |
|---|--------|-------------------------|-------------------------|------------|------------------|
| 50%   | 65800  | 5.3                     | 5.34                    | 100.8%     | 100.51%          |
| 100%  | 124353 | 10                      | 10.10                   | 100.01%    |                  |
| 150%  | 177940 | 14.2                    | 14.45                   | 99.68%     |                  |

**Table 8:** Area of different concentration of Tiotropium

| S.No.                   | Linearity Level | Concentration | Area    |
|-------------------------|-----------------|---------------|---------|
| 1                       | I               | 100ppm        | 668934  |
| 2                       | II              | 200ppm        | 956781  |
| 3                       | III             | 300ppm        | 1313873 |
| 4                       | IV              | 400ppm        | 1563458 |
| 5                       | V               | 500ppm        | 1867084 |
| Correlation Coefficient |                 |               | 0.997   |

**Table 9:** Area of different concentration of Salmeterol

| S.No.                   | Linearity Level | Concentration | Area   |
|-------------------------|-----------------|---------------|--------|
| 1                       | I               | 1ppm          | 66510  |
| 2                       | II              | 2ppm          | 94701  |
| 3                       | III             | 3ppm          | 124802 |
| 4                       | IV              | 4ppm          | 152731 |
| 5                       | V               | 5ppm          | 179732 |
| Correlation Coefficient |                 |               | 0.997  |

**Table 10:** Analytical performance parameters of Tiotropium and Salmeterol

| Parameters                        | Tiotropium | Salmeterol |
|-----------------------------------|------------|------------|
| Slope (m)                         | 66574      | 12529      |
| Intercept (c)                     | 53592      | 50245      |
| Correlation coefficient ( $R^2$ ) | 0.999      | 0.999      |

**Table 11:** Results of LOD

| Drug name  | Baseline noise( $\mu$ V) | Signal obtained ( $\mu$ V) | S/N ratio |
|------------|--------------------------|----------------------------|-----------|
| Tiotropium | 52                       | 152                        | 2.9       |
| Salmeterol | 52                       | 156                        | 3         |

**Table 12:** Showing system suitability results for Sitagliptin

| S. No | Flow rate (ml/min) | System suitability results |             |
|-------|--------------------|----------------------------|-------------|
|       |                    | USP Plate Count            | USP Tailing |
| 1     | 0.8                | 5435                       | 1.04        |
| 2     | 1                  | 4891                       | 1.03        |
| 3     | 1.2                | 4781                       | 1.04        |

**Table 13:** Results of LOQ

| Drug name  | Baseline noise( $\mu$ V) | Signal obtained ( $\mu$ V) | S/N ratio |
|------------|--------------------------|----------------------------|-----------|
| Tiotropium | 52                       | 522                        | 10.03     |
| Salmeterol | 52                       | 524                        | 10.1      |

**Table 14:** Flow Rate (ml/min) data for Tiotropium

| S.No | Flow Rate (ml/min) | System Suitability Results |             |
|------|--------------------|----------------------------|-------------|
|      |                    | USP Plate Count            | USP Tailing |
| 1    | 0.6                | 5339.9                     | 1.4         |
| 2    | 0.8                | 4673.4                     | 1.3         |
| 3    | 1.0                | 5216.0                     | 1.4         |

**Table 15:** Flow rate (ml/min) data for Salmeterol

| S.No | Flow Rate (ml/min) | System Suitability Results |             |
|------|--------------------|----------------------------|-------------|
|      |                    | USP Plate Count            | USP Tailing |
| 1    | 0.8                | 7063.3                     | 1.3         |
| 2    | 1.0                | 6090.3                     | 1.2         |
| 3    | 1.2                | 6998.0                     | 1.3         |

**Table 16:** Change in Organic Composition in the Mobile Phase for Tiotropium

| S.No | Change in Organic Composition in the Mobile Phase | System Suitability Results |             |
|------|---|----------------------------|-------------|
|      |   | USP Plate Count            | USP Tailing |
| 1    | 10% less  | 4508.4                     | 1.3         |
| 2    | *Actual   | 4673.4                     | 1.4         |
| 3    | 10% more  | 4318.1                     | 1.3         |

**Table 17:** Change in Organic Composition in the Mobile Phase for Salmeterol

| S.No | Change in Organic Composition in the Mobile Phase | System Suitability Results |             |
|------|---|----------------------------|-------------|
|      |   | USP Plate Count            | USP Tailing |
| 1    | 10% less  | 6387.7                     | 1.2         |
| 2    | *Actual   | 6090.3                     | 1.2         |
| 3    | 10% more  | 6232.5                     | 1.2         |

#### 4. Conclusion

From the above experimental results and parameters, it was concluded that, this newly developed method for the simultaneous estimation Tiotropium and Salmeterol was found to be simple, precise, accurate and high resolution and shorter retention time makes this method more acceptable and cost effective and it can be effectively applied for routine analysis in research institutions, quality control department in meant in industries, approved testing laboratories studies in near future.

#### 5. Reference

- [1] Beckett A.H and Stenlake J.B; text book of pharmaceutical chemistry 4th Edn,-part 2 CBS publishers and Distributors, New Delhi, 1998; 278, 307 Vol 4, (3).
- [2] Douglas Skoog A., James Holler F. and Timothy Nieman., A Principles of Instrumental Analysis. 5<sup>th</sup> ed., Thomson Learning Inc. Singapore, 1998; 110, 300, Vol 2.
- [3] Sethi, P.D., Quantitative Analysis of Drugs in Pharmaceutical formulation, 3<sup>rd</sup> ed., CBS Publishers and Distributors, 1997; 1-29, 50-64, Vol 3.
- [4] Mendham, R.C., Denny, J.D., Barnis, M. and Thomas, J.K., Vogel's Text Book of Quantitative Chemical Analysis, 6<sup>th</sup> ed., Pearson Education, 2003; 1, 676.
- [5] Sharma, B.K., Instrumental method of Chemical Analysis, 24<sup>th</sup> ed., GOEL Publishing House, Meerut, 2005; 46, 68.